



Cell IDx



Contact:

David Schwartz, PhD

Location:

San Diego

Email:

david_schwartz@cellidx.com

Tel:

1-858-452-5800

Website:

<http://www.cellidx.com>



Company Profile

Industry Sector: Biotechnology

Company Overview: Cell IDx has developed a new platform technology for advanced molecular profiling of diagnostic biopsies. UltraPlex multiplex immunofluorescence allows simple, rapid and simultaneous staining of multiple markers in tissue biopsies, far superior to current methods of single marker staining or current laborious methods of multiplexing.

Target Market(s): Pharmaceutical companies, CROs, research institutes.



Key Value Drivers

Technology*: Cell IDx's UltraPlex multiplex immunofluorescence technology allows rapid detection of multiple markers simultaneously on a single, small tissue sample.

Competitive Advantage: Our technology is significantly simpler, faster and provides critical new information needed by the current new generation of immunotherapeutics not provided by standard pathology techniques or other multiplex technologies.

Plan & Strategy:

1. Launch new website to coincide with product release
2. Offer standard multiplex research panels online
3. Partner with pharmaceutical companies and CROs to generate custom multiplex panels



Management

Leadership:

David Schwartz, PhD: CEO, CSO and Founder

Helen Snyder, PhD: Director of Business Development

Scientific Advisory Board:

Stephen Kron, MD, PhD: Chair and Founder, Professor of Molecular Genetics and Cell Biology at the University of Chicago



Product Pipeline

1. Pipeline One: Breast Cancer Multiplex IVD panels

2. Pipeline Two: Human Immune Multiplex RUO Panels

3. Pipeline Three: Mouse Immune Multiplex RUO Panels



Small Business Innovation Research (SBIR)
Small Business Technology Transfer (STTR)

National Institutes of Health
Commercialization Assistance Program (NIH CAP)

